News Crossject Deutsche Boerse AG

Equities

74C

FR0011716265

Market Closed - Deutsche Boerse AG Other stock markets 11:32:11 16/07/2024 am IST			5-day change	1st Jan Change
1.826 ^EUR	+2.70%		+16.16%	-59.78%

10/07	Markets Powered by Alternating Current
10/07	Crossject Gets EUR7 Million Public Funding for New Epinephrine Product	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference	15/07	GL
Markets Powered by Alternating Current	10/07
Crossject Gets EUR7 Million Public Funding for New Epinephrine Product	10/07	MT
Crossject: public financing secured until 2026	10/07	CF
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine	10/07	GL
Crossject Receives EUR 6.9 Million Public Funding from the French Government, as Part of the France 2030 Innovation Plan, to Accelerate the Development of ZENEO Epinephrine	10/07	CI
Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	27/06	AQ
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	26/06	GL
Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America	13/06	CI
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	12/06	GL
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	12/06	AQ
Crossject: successful capital increase	05/06	CF
CROSSJECT : Success of the capital increase	05/06	AL
Crossject Raises EUR8 Million via Rights Offering	05/06	MT
Crossject announces highly successful closing of its €8 million rights offering	04/06	GL
Crossject Société Anonyme announced that it has received ?7.999999 million in funding	04/06	CI
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy	30/05	GL
Crossject: capital increase until May 30	27/05	CF
Crossject: praised for extended agreement on Zepizure	03/05	CF
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe	02/05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Crossject Deutsche Boerse AG

Equities

74C

FR0011716265

Summary

Filters